Effects of Resistant Starch on Symptoms, Fecal Markers and Gut Microbiota in Parkinson’s Disease – The RESISTA-PD Trial
Open accessPreprint — published as 10.1016/j.gpb.2021.08.009 · Paper page
Abstract
The composition of the gut microbiome is linked to multiple diseases, including Parkinson’s disease (PD). Bacteria producing short-chain fatty acids (SCFAs) and fecal SCFA concentrations are reduced in PD. SCFAs exert various beneficial functions in humans. In the interventional, monocentric, open-label clinical trial RESISTA-PD ( NCT02784145 ) we aimed at altering fecal SCFAs by an 8-week prebiotic intervention with resistant starch (RS). We enrolled 87 subjects in three study-arms: 32 PD patients receiving RS (PD + RS), 30 control subjects receiving RS, and 25 PD patients receiving solely dietary instructions. We performed paired-end 100 base pair length metagenomic sequencing of fecal samples using the BGISEQ platform at an average of 9.9 GB. RS was well-tolerated. In PD + RS, fecal butyrate concentrations increased significantly and fecal calprotectin concentrations dropped significantly after 8 weeks of RS. Clinically, we observed a reduction in non-motor symptoms load in PD + RS. The reference-based analysis of metagenomes highlighted stable alpha-diversity and beta-diversity across the three groups, including bacteria producing SCFAs. Reference-free analysis suggested punctual, yet pronounced differences in the metagenomic signature in PD + RS. RESISTA-PD highlights that a prebiotic treatment with RS is safe and well-tolerated in PD. The stable alpha-diversity and beta-diversity alongside altered fecal butyrate and calprotectin concentrations calls for long-term studies, also investigating whether RS is able to modify the clinical course of PD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Altered GM could contribute to the onset of some PD-related complications, such as constipation.
“Concerning PD, as previously mentioned, altered GM could contribute to the onset of some PD-related complications, such as constipation, the most common non-motor symptom [316].”
From The Interplay between Gut Microbiota and Parkinson’s Disease: Implications on Diagnosis and Treatment (2022) · cites this paper as [316]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 59 · Cited by 102
- Authors
- Becker, A., Schmartz, G. P., Gröger, L., Grammes, N., Galata, V., Philippeit, H., Weiland, J., Ludwig, N., Meese, E., Tierling, S., Walter, J., Schwiertz, A., Spiegel, J., Wagenpfeil, G., Faßbender, K., Keller, A., & Unger, M. M.
- Affiliations
- Saarland University (DE)
- Institut für Mikroökologie (DE)
- Corresponding author
- Unger, Marcus M.
- ORCID
- Venue
- Genomics Proteomics & Bioinformatics
- Publisher
- openRxiv
- Published
- 2021-02-08
- Volume
- 20
- Issue
- 2
- Pages
- 274-287
- ISSN
- 1672-0229 (ISSN-L)
- PMC
- PMC9684155
- OpenAlex
- W3214815292
- Cited by
- 102
- References
- 59
- Citations by year
- 2026: 16 · 2025: 31 · 2024: 28 · 2023: 13 · 2022: 12 · 2021: 2
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Genomics Proteomics & Bioinformatics (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Publications of the UdS (Saarland University) (cc-by)
- Funders
- Michael J. Fox Foundation for Parkinson's Research (14603)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- resistant starch, Parkinson's disease, gut microbiota, short-chain fatty acids, butyrate, calprotectin, non-motor symptoms, fecal microbiota, metagenomics, dietary intervention
- MeSH terms
- Gastrointestinal Microbiome, Resistant Starch, Bacteria, Butyrates, Fatty Acids, Volatile, Feces, Humans, Parkinson Disease, Biomarkers, Leukocyte L1 Antigen Complex, Prebiotics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
